Organic Active Ingredients TRIZ Cases

An aqueous oral cannabinoid solution uses alcohol and propylene glycol to dissolve the active ingredient.

Modified sugar moieties and nucleobase compositions in these compounds boost interferon potency for antiviral and anti-cancer therapies.

Modified oligonucleotides reduce GCGR mRNA expression to treat metabolic disorders where current therapies fail to suppress glucagon levels.

Cis-gnetin H overcomes trans-gnetin H instability by improving chemical stability while maintaining anti-tumor activity.

Combining halobetasol and tazarotene creates a synergistic topical composition.

A novel indole derivative acts as an EP1 receptor antagonist to treat overactive bladder syndrome.

Indoline analogs target EWS-FLI1 to block tumor growth, addressing delivery and stability issues in current cancer therapies.

Compounds of formula I and II inhibit Baltimore Group IV RNA virus infections by targeting viral proteases.

Lanosterol prodrug eye drops reverse cataracts by preventing protein aggregation, avoiding surgical complications.

A pirfenidone dose escalation scheme reaches full therapeutic dosage by Day 15 through a three-step regimen.

SEMA3C inhibitors block pro-survival signaling to induce apoptosis, extending progression-free survival beyond transient androgen suppression.

Precipitating a glucocorticoid receptor antagonist from solution yields an amorphous solid form suitable for pharmaceutical processing.

Triazolopyrimidine compound resolves selectivity and stability trade-offs by enhancing neuronal plasticity for neurological disorder treatment.

A pharmaceutical dosage form uses specific cyclobutane compounds to stabilize fumaric acid esters against degradation.

BRAF-specific siRNA binds synovial fibroblast mRNA to inhibit translation and reduce cell proliferation.

Formula I compounds inhibit NS5A replication, reducing side effects and overcoming genetic heterogeneity in hepatitis C treatment.

Actin depolymerization increases muscle strength without physical exercise, bypassing time-intensive resistance training.

Hydroxamic acid derivatives enhance antitumor activity through structural conjugation with chemotherapeutic agents.

A twice-daily JAK inhibitor regimen transitions to once-daily dosing to manage clinical signs of atopic dermatitis.

Double-stranded ribonucleic acid mediates RNA interference to silence PCSK9 gene expression, reducing LDL cholesterol levels for hyperlipidemia treatment.

Glucosylceramide from Amorphophallus konjac tuber suppresses amyloid beta protein accumulation in brain tissue.

Miltefosine and sulfatide activate type II NKT cells to suppress type I NKT-mediated tissue damage in alcoholic liver disease.

A miRNA-520f molecule induces mesenchymal to epithelial transition by targeting transcriptional repressors of E-cadherin.

Targeting the C19MC microRNA cluster reduces side effects from conventional infantile hemangioma treatments while clarifying underlying pathogenesis mechanisms.

Segmented biodegradable clonidine depots release analgesic via polymer diffusion, reducing opioid side effects while sustaining pain relief.

Sodium alginate creates a protective gel barrier to stabilize oral peptides, eliminating secondary acid formation from carbonate-based medications.

Cashew apple extract inhibits pancreatic lipase activity, reducing body weight gain and fatty liver while avoiding side effects of synthetic drugs.

A new synthesis method for 2,4,5-trisubstituted 1,2,4-triazolone compounds uses tetrahydropyranylether protection to secure high yields.

Modified 4-phenyl pyridine structures selectively stimulate TGR5 receptors, managing Type II diabetes without hypoglycemia or weight gain.

A cefuroxime axetil suspension formulation uses citric acid and trisodium citrate to prevent gel formation.

A refluxing mixture with aliphatic solvents condenses vapors and returns them to the reaction vessel using molecular sieves.

Injecting collagenase into the flexor retinaculum weakens its structural integrity to reduce carpal tunnel pressure.

GDF traps antagonize inhibitory ligands to boost red blood cell formation with lower EPO doses, reducing cardiovascular risks.

Combines alexidine dihydrochloride with sodium pentaborate pentahydrate to target pancreatic cancer cells.

CRISPR-Cas9 systems eliminate variant NRF2 expression to overcome chemoresistance and restore drug sensitivity.

Bioadhesive NanoTabs adhere to oral mucosa to bypass gastrointestinal metabolism, ensuring consistent bioavailability and reducing abuse potential.

Novel heterocyclic compounds inhibit casein kinase 1 to overcome resistance and improve treatment efficacy in chronic lymphocytic leukemia.

Formula I compounds act as selective mu opioid receptor agonists to deliver potent analgesic effects while reducing tolerance and abuse liability.

Oblique mixing in a multi-port manifold controls nanoparticle size distribution, resolving scalability limits and product heterogeneity.

Substituted quinoline compounds modulate nuclear receptor RORγt activity to target the Th17 pathway.

An amorphous solid form of a BET protein inhibitor provides high stability and purity through aqueous preparation.

Conjugating Globo H with DT-CRM197 and C34 adjuvant overcomes low antigenicity to delay tumorigenesis in breast cancer models.

Malic acid masks bitter uncoated NSAIDs under 100 microns, resolving the contradiction between rapid dissolution and unpleasant mouthfeel.

Intermediate binding compounds react covalently with tetrazine ligands to prevent in vivo decomposition and reduce background radiation.